Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Chronic Depression: a Double-blind Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20 to 75 years (ages 20 to 60 for MRI sub-study)~* diagnosis of dysthymic disorder (chronic depression) or depression NOS~* minimum of 2 years duration of current episode of depression~Exclusion Criteria:~* current major depression~* diagnoses including delirium, dementia, bipolar disorder, schizophrenia~* substance abuse or dependence in the past 6 months~* pregnant or nursing women~* serious risk of suicide

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- duloxetine (cymbalta) (Type: EXPERIMENTAL): Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
- Placebo treatment (Type: PLACEBO_COMPARATOR): placebo treatment: treatment with placebo capsules that match active medication capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).